Superworth

Korro Bio EPS KRRO

Diluted earnings per share by quarter and over the last twelve months, from 2018.

Last 12 months, to Jun 30, 2026
−$10.00
Latest quarter, Q2 FY26
−$1.07
Fiscal year 2025
−$12.47

Korro Bio's earnings per share was −$10.00 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$1.07.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$12.47n/a
FY2024−$9.39n/a
FY2021−$123.50n/a
FY2020−$40.50n/a
FY2019−$379.00n/a
FY2018n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$1.07n/a−$10.00
Q1 FY26−$1.69n/a−$11.67
Q4 FY25−$5.32n/a−$12.47
Q3 FY25−$1.92n/a−$9.41
Q2 FY25−$2.74n/a−$9.75
Q1 FY25−$2.49n/a−$9.44
Q4 FY24−$2.26n/a−$9.39
Q3 FY24−$2.26n/an/a
Q2 FY24−$2.43n/an/a
Q1 FY24−$2.44n/an/a
Q3 FY23−$65.08n/an/a
Q2 FY23−$63.83n/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Korro Bio's size, closest first, today.

CompanyEPS, 12 monthsGrowth
KRROKorro Bio−$10.00
NATRNatures Sunshine Products$1.01+36% a year
LFVNLifevantage$0.40−46% a year
ARVNArvinas$0.16
SPROSpero Therapeutics$0.11
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
ATNMActinium Pharmaceuticals$0.36
COLLCollegium Pharmaceutical$1.24+19% a year
Peer median$0.65

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Korro Bio

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.